Published in Clin Dermatol on November 02, 2009
A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40
Post-embryonic nerve-associated precursors to adult pigment cells: genetic requirements and dynamics of morphogenesis and differentiation. PLoS Genet (2011) 1.28
Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One (2012) 1.21
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res (2010) 1.07
The environmental stressor ultraviolet B radiation inhibits murine antitumor immunity through its ability to generate platelet-activating factor agonists. Carcinogenesis (2012) 1.05
Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes. PLoS One (2012) 0.97
Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Res (2014) 0.97
Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma. Ann Dermatol (2013) 0.92
Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep (2012) 0.89
Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther (2011) 0.88
Melanoma resistance to photodynamic therapy: new insights. Biol Chem (2013) 0.86
The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis. PLoS One (2013) 0.85
Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol (2014) 0.85
Use of gene expression and pathway signatures to characterize the complexity of human melanoma. Am J Pathol (2011) 0.81
Insights into the Role of PAX-3 in the Development of Melanocytes and Melanoma. Open Cancer J (2011) 0.81
Expression of the platelet-activating factor receptor enhances benzyl isothiocyanate-induced apoptosis in murine and human melanoma cells. Mol Med Rep (2015) 0.80
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One (2013) 0.78
Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS One (2015) 0.77
Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Ther Adv Med Oncol (2015) 0.76
Vitamin E δ-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells. Sci Rep (2016) 0.76
Components in aqueous Hibiscus rosa-sinensis flower extract inhibit in vitro melanoma cell growth. J Tradit Complement Med (2016) 0.75
RGDechi-hCit: αvβ3 selective pro-apoptotic peptide as potential carrier for drug delivery into melanoma metastatic cells. PLoS One (2014) 0.75
Functional Modulation of Regulatory T Cells by IL-2. PLoS One (2015) 0.75
Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression. PLoS One (2015) 0.75
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res (2004) 3.64
Ipilimumab: a promising immunotherapy for melanoma. Oncology (Williston Park) (2010) 2.79
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28
Advances in the systemic treatment of metastatic melanoma. Oncology (Williston Park) (2013) 2.05
High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res (2007) 1.88
Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res (2004) 1.80
Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res (2008) 1.50
Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol (2009) 1.33
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res (2003) 1.31
Characterizing disease states from topological properties of transcriptional regulatory networks. BMC Bioinformatics (2006) 1.27
Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci U S A (2008) 1.26
Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel. Lancet Oncol (2006) 1.20
alphaB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer (2004) 1.20
Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res (2004) 1.18
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res (2005) 1.13
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One (2012) 1.12
Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res (2008) 1.11
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol (2009) 1.08
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res (2010) 1.07
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res (2009) 1.06
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res (2009) 1.03
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res (2006) 1.01
MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer (2014) 0.98
Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer. Cancer Res (2007) 0.98
Rab33A: characterization, expression, and suppression by epigenetic modification. J Invest Dermatol (2006) 0.98
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res (2009) 0.97
Advances in therapy for melanoma brain metastases. Clin Dermatol (2013) 0.95
Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin Cancer Res (2005) 0.95
CD70 expression patterns in renal cell carcinoma. Hum Pathol (2012) 0.92
Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer (2011) 0.90
Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep (2012) 0.89
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med (2011) 0.88
Vascularity of primary and metastatic renal cell carcinoma specimens. J Transl Med (2013) 0.86
In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell Melanoma Res (2011) 0.83
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Res (2010) 0.83
Immunotherapy for metastatic melanoma. J Cell Biochem (2012) 0.81
Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. J Clin Oncol (2011) 0.81
Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clin Pathol (2013) 0.81
Vertical pathway targeting in cancer therapy. Adv Pharmacol (2012) 0.80
Molecular alternations in uveal melanoma. Curr Probl Cancer (2011) 0.80
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One (2013) 0.78
Studies of NVP-BEZ235 in melanoma. Curr Cancer Drug Targets (2013) 0.78
Assessing expression of apoptotic markers using large cohort tissue microarrays. Methods Mol Biol (2008) 0.77
Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmgenomics Pers Med (2012) 0.77
Radiation sensitivity and sensitization in melanoma. Pigment Cell Melanoma Res (2013) 0.76
Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma. J Immunother (2017) 0.75
From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma. Cancer J (2017) 0.75